Abstract Details

Title Can Art Therapy improve signs and symptoms of Parkinson's Disease? Preliminary Results from the "ExplorArtPD Study"

Topic Movement Disorders

Presentation(s) P2 - Poster Session 2 (5:30 PM-6:30 PM)

Poster/Presentation
Number 10-013

Objective Preliminary analysis to characterize visuospatial abnormalities in Parkinson's disease (PD) and to explore the rehabilitative potential of a novel program of Art Therapy (AT) on visuospatial and motor dysfunction.

Background In PD, visuospatial dysfunction correlates with reduced quality of life and poorer prognosis. Systematic biases in space perception and multisensory integration may affect essential motor skills like locomotion and balance maintenance.

Design/Methods

Dual-phase exploratory study. 1: cross-sectional, controlled, biomarker study on 30 non-demented PD (H&Y 2-3) and 30 age-matched controls; 2: prospective, open label study involving 20 sessions of AT (2 sessions/week). Motor and gait functions were assessed by MDS-UPDRS, TimedUpandGo test (TUG), and wearable accelerometers. Cognitive and Visuospatial functions were assessed by neuropsychological inventories (MoCA, Rey-OsterriethFigureTest, BentonVisualTest) and computerized testing (NavonVisualTest, VisualResearchTest, and reaction time), and binocular eye tracking (Eyelink 2). Psychological wellness was assessed by Beck Depression Index (BDI), Modified Fatigue Impact Scale, and PROMIS-Self-Efficacy scales. Brain imaging included T1-weighted 3D high resolution, DWI, and RS-fMRI sequences. Preliminary analyses were conducted on clinical data from 18 PD-patients and 14 controls completing the study. Eye tracking from 4 subjects was analyzed for exploratory purposes.

Results PD-patients and controls were significantly different with respect to BDI score, NavonVisualTest (total time and number of errors), ReyFigureTest, UPDRS-III, and TUG-3 (maximum gait speed). Following AT, PD patients showed significant improvements in UPDRS-III, UPDRS-total, PROMIS (symptoms management), and NavonVisualTest (number of errors). A strong trend towards improved ReyeFigureTest was observed. On eye tracking analysis, significant increases in exploratory eye movements and fixation patterns were observed spatiotopically during examined stimulus regions.

Conclusions In PD, AT may improve visual-constructional abilities, visual recognition, and motor function. These improvements were associated with improved self-efficacy and changes in oculomotor behavior characterized by a more efficient visual exploration strategy. These preliminary results must be validated through a larger sample and appropriately controlled intervention.

Authors/Disclosures
Alberto Cucca, MD (The Marlene and Paolo Fresco Institute for Parkinsons and Movement Disorders) PRESENTER	No disclosure on file
Kush Sharma, MBBS	Dr. Sharma has nothing to disclose.
	No disclosure on file
Mahya Beheshti, MBBS (The Mount Sinai Hospital)	No disclosure on file
	No disclosure on file
	No disclosure on file
Andrew S. Feigin, MD (NYU Langone Health)	Dr. Feigin has received personal compensation for serving as an employee of Rho, Inc.. Dr. Feigin has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Kenai. Dr. Feigin has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for ADCS/ATRI. Dr. Feigin has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for PTC. Dr. Feigin has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB. Dr. Feigin has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lundbeck. The institution of Dr. Feigin has received research support from Huntngton Study Group. The institution of Dr. Feigin has received research support from Prilenia.
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
Milton Biagioni, MD (UCB Biopharma SRL)	No disclosure on file

��ɫ��

��ɫ��